Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCEH1 | Q6PIU2 | 16/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL829420 | 0.86 | NCEH1 (0.67) | NCEH1RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL830202 | 0.80 | NCEH1 (1.00) | NCEH1RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL27861350 | 0.77 | ACHE (0.46) | RAB9ANPC1SMN1; SMN2MAPTHPGD | |
| SCHEMBL829484 | 0.75 | NCEH1 (0.62) | NCEH1RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL829227 | 0.74 | SMN1; SMN2 (1.00) | NCEH1RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL4190695 | 0.73 | ABCC1 (0.60) | NPC1SMN1; SMN2MAPTCYP1A2CYP3A4 | |
| SCHEMBL27547560 | 0.72 | NCEH1 (0.69) | NCEH1RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL829284 | 0.71 | NCEH1 (0.65) | NCEH1RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL9658102 | 0.71 | ATM (0.43) | RAB9ANPC1SMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL19439381 | 0.71 | NCEH1 (0.67) | NCEH1RAB9ANPC1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143257-B2 | inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester | PTC THERAPEUTICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | PTC THERAPEUTICS, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | VEGFA, FLT4, FLT1 | NCEH1 3211/4885RAB9A 3160/4885NPC1 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.